TENAX Therapeutics, Inc. (NASDAQ: TENX) released a comprehensive LEVEL clinical-trial update showing a 49% reduction in NT-proBNP, while the study’s primary endpoint did not reach statistical significance. The results update covers the company’s levosimendan development program and was made public on September 9, 2026. …
Tyra Biosciences, Inc. (NASDAQ: TYRA) identified oral dabogratinib at 60 mg once daily as a potential dose for its planned registrational adjuvant strategy in a bladder cancer population with FGFR3 alterations. SURF302 produced an overall response rate of 79%, or 11 of 14 evaluable …
UroGen Pharma Ltd. (NASDAQ: URGN) General Counsel Jason Drew Smith sold 1,519 shares at $42.54 per share on Sep. 8. His share ownership afterward stood at 53,141 shares.
UroGen Pharma Ltd. (NASDAQ: URGN) Chief Medical Officer Mark Schoenberg exercised options for 1,667 shares on Sep 7, leaving him with 60,753 shares. The next day, he sold 871 shares at $42.92 per share, after which his reported holding stood at 59,882 shares.
ProQR Therapeutics N.V. (NASDAQ: PRQR) has dosed the first participant in its AX-0811 clinical study, advancing the RNA editing candidate into testing in healthy volunteers. The study will examine safety, tolerability, pharmacokinetics and pharmacodynamic biomarkers for a potential treatment targeting cholestatic liver diseases, including …
Pyxis Oncology, Inc. (NASDAQ: PYXS) reported updated Phase 1 results for MICVO that support advancing the drug into a key program after a 36% confirmed objective response rate, or 12 of 33 efficacy-evaluable patients. The study evaluated patients with second-line and beyond recurrent or …
QIAGEN N.V. (NYSE: QGEN) appointed Jonathan M. Pratt as chief executive officer effective September 1, 2026, succeeding Thierry Bernard. Bernard also stepped down from the Managing Board on that date, while QIAGEN reaffirmed its third-quarter and full-year 2026 outlook.
RAD301 Shows Selective Pancreatic Tumor Uptake
Satellos Bioscience Inc. (NASDAQ: MSLE) will use forazapadin as the international nonproprietary name for its lead drug candidate, previously known as SAT-3247. The orally administered small molecule is being evaluated in clinical studies for Duchenne muscular dystrophy, while Satellos intends to begin a trial …
SERA PROGNOSTICS, INC. (NASDAQ: SERA) shares held by Chief Executive Officer Lindgardt Zhenya fell by 20,139 at a transaction price of $2 per share. The sale took place on September 8, 2026. The reported sale price was $2 per share.